News Image

Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Provided By GlobeNewswire

Last update: Feb 4, 2025

ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the receipt of the Israeli Medical Device Division of the Ministry of Health’s (AMAR) approvals for the FemaSeed® Intratubal Insemination product for female infertility treatment and two diagnostic devices, FemVue® for tubal evaluation and FemCerv® for cervical cancer detection.

Read more at globenewswire.com

FEMASYS INC

NASDAQ:FEMY (4/25/2025, 8:05:42 PM)

1.23

-0.01 (-0.81%)



Find more stocks in the Stock Screener

Follow ChartMill for more